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Abstract
Background: Platelets secrete many pro-wound healing molecules such as growth 
factors and cytokines. We found that releasates from activated human platelets 
induced the differentiation of cultured murine and human fibroblasts into a myofi-
broblast phenotype. Surprisingly, most of this differentiation-inducing activity was 
heat-stable, suggesting it was not due to the protein component of the releasates. 
Inorganic polyphosphate is a major constituent of platelet-dense granules and pro-
motes blood coagulation and inflammation.
Objectives: We aim to investigate the contribution of polyphosphate on myofibro-
blast differentiating activity of platelet releasates.
Methods: Using NIH-3T3 cells and primary human fibroblasts, we examined the ef-
fect of human platelet releasates and chemically synthesized polyphosphate on fi-
broblast differentiation and migration.
Results: We found that the myofibroblast-inducing activity of platelet releasates 
was severely attenuated after incubation with a polyphosphate-degrading enzyme, 
and that fibroblasts responded to platelet-sized polyphosphate by increased levels 
of α-smooth muscle actin, stress fibers, and collagen. Furthermore, fibroblasts were 
chemotactic toward polyphosphate.
Conclusions: These findings indicate that platelet-derived polyphosphate acts as a 
cell signaling molecule by inducing murine and human fibroblasts to differentiate into 
myofibroblasts, a cell type known to drive both wound healing and fibrosing diseases. 
Polyphosphate therefore not only promotes early wound responses through enhanc-
ing fibrin clot formation, but also may play roles in the later stages of wound healing, 
and, potentially, progression of fibrotic diseases, by recruiting fibroblasts and induc-
ing their differentiation into myofibroblasts.
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1  | INTRODUC TION
Polyphosphate is a simple inorganic molecule, consisting of lin-
ear polymers of phosphate groups that range in length from 
a few phosphates to more than a thousand phosphates long.1 
Polyphosphate has been identified in all kingdoms of life, making it 
a remarkably conserved molecule.2 The majority of polyphosphate 
studies has been performed in prokaryotes, where polyphosphate 
has roles in stress endurance, quorum sensing, virulence, phos-
phate storage, biofilm formation, and heavy metal resistance.3-9 
In unicellular eukaryotes, polyphosphate has roles in germination, 
development, migration, nutrient homeostasis, proliferation, and 
differentiation.10-15
Although the roles and modes of action of polyphosphate in 
mammalian cells are less understood, extracellular polyphosphate 
is an emerging regulatory molecule with recently identified func-
tions including blood clotting, complement, biomineralization, in-
flammation, differentiation, and cell migration.16-25 Polyphosphate is 
contained in the dense granules of platelets, and upon platelet acti-
vation it is released into the microenvironment where it modulates 
coagulation and fibrinolysis by enhancing fibrin clot structure, acting 
as cofactor for the activation of factor XI by thrombin, accelerating 
factor V activation by factor XIa, and acting as cofactor for inac-
tivation of alpha tissue factor pathway inhibitor by factor XIa.26-31 
Platelet-derived polyphosphate acts as a pro-inflammatory and pro-
coagulant molecule for endothelial cells by increasing adhesion mol-
ecule expression and von Willebrand factor secretion.17,18,32
Polyphosphate released from activated platelets induces differ-
entiation of monocytes into fibrocytes, a circulating cell type that 
can promote scar tissue.24 These findings raise the possibility that 
polyphosphate secreted by activated platelets may act as a cell sig-
naling molecule in wound healing for other cell types. Tissue resident 
fibroblasts are known to be recruited to wound or injury sites and to 
differentiate into myofibroblasts, which generate contractile force 
and secrete tissue matrix proteins to aid in wound closure and scar 
formation.33 Myofibroblasts are also the primary effector cells driv-
ing fibrotic disease, in which the wound healing process becomes 
dysregulated in otherwise healthy organs or tissues, which in turn 
can lead to cellular dysfunction, organ failure, and death.34,35 There 
is currently no cure for fibrosis, which contributes to up to 45% of 
all deaths in the United States.36 We now report that platelet poly-
phosphate is chemotactic for mouse and human fibroblasts, and that 
it potently induces their differentiation into myofibroblasts.
2  | METHODS
2.1 | Materials
α-Smooth muscle actin (α-SMA) antibody (14-9760-82), goat anti-
mouse IgG2a secondary antibody (A-21133), Dulbecco's Modified 
Eagle Medium (DMEM), SYBR Green I, polycarbonate cell culture 
inserts, ProLong Gold Antifade Mountant, and CyQUANT Cell 
Proliferation Assay were from Thermo Fisher Scientific. Bovine calf 
serum, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 
Tween 20, and Triton X-100 were from Fisher Scientific. Collagen 
1 (84336) and vimentin (5741) antibodies were from Cell Signaling 
Technology. The PAR-1 selective activating peptide, TRAP (S1820), 
prostaglandin E1, theophylline, sodium pyrophosphate, and sodium 
tripolyphosphate were from Sigma-Aldrich. Phalloidin-iFluor 647 
(ab176759) was from Abcam. Goat anti-rabbit IgG was from Jackson 
ImmunoResearch Labs. Poly-L-Lysine was from ScienCell Research 
Laboratories. L-glutamine, penicillin/streptomycin, and insulin-trans-
ferrin-selenium were from Corning. The P2Y1 receptor competitive 
antagonist MRS 2279 was from Tocris.
Narrowly sized fractioned polyphosphate was produced from 
chemically synthesized polyphosphate by preparative PAGE as pre-
viously described.37 Approximately platelet-sized polyphosphate, 
with a modal polymer length of 75 phosphates and a range of 20 
to 280 phosphates, was prepared using differential acetone precip-
itation of P70 (a more heterogeneous, chemically synthesized poly-
phosphate preparation that was a kind gift from Dr Thomas Staffel, 
BK Giulini GmbH). Briefly, to a stirred solution of 500 mmol/L P70 
in 100 mmol/L NaCl, acetone was gradually added to a final concen-
tration of 12.2% v/v. The precipitated polyphosphate was collected 
by centrifugation for 20 minutes at 13 000g, dried under nitrogen 
gas, and dissolved in a solution of 20 mmol/L Hepes-NaOH buffer 
(pH 7.4). Polyphosphate concentrations were quantified as inorganic 
phosphate after acid hydrolysis as previously described.38 In this 
paper, polyphosphate concentrations are given in terms of the con-
centration of phosphate monomer.
2.2 | Cell culture
The murine embryonic fibroblastic cell line, NIH-3T3 (ATCC CRL-
1658), and primary human dermal fibroblasts, GM1381 (Coriell 
Institute), were routinely cultured in DMEM supplemented with 
10 mmol/L HEPES, penicillin, streptomycin, 4 mmol/L L-glutamine, 
and 10% bovine calf serum, in a 5% CO2 environment at 37°C. Cells 
were maintained at <90% confluence and were cultured for no more 
than 2 weeks at a time. Experiments performed in serum-free media 
were cultured in DMEM supplemented as detailed previously, with-
out serum but with the addition of insulin-transferrin-selenium.
Essentials
• Polyphosphate is released from activated platelets.
• Platelet releasates induce myofibroblast differentiation.
• Platelet-sized polyphosphate promotes migration and 
myofibroblast differentiation.
• Platelet polyphosphate acts as a pro-wound healing and 
chemotactic molecule for fibroblasts.
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2.3 | Platelet releasates
Recently expired platelet units were kindly provided by the University 
of Michigan Blood Bank. Platelet releasates were prepared as de-
scribed.29 Briefly, platelets were washed in Tyrode's buffer and sus-
pended in the same buffer at 2.0 × 109 platelets/mL, then incubated 
with 5 µmol/L TRAP to activate the platelets. After 20 minutes, plate-
lets were removed by centrifugation, and the protein content was 
estimated using a NanoDrop 1000 spectrophotometer (assuming an 
A280 of 1 equals 1 mg/mL protein). Protein concentrations in such 
releasates averaged 415 ± 86 µg/mL (mean ± standard deviation). 
Releasates were diluted to 300 µg/mL protein in Tyrode's buffer con-
taining 10 mmol/L EDTA (to inhibit phosphatases), then filter-sterilized 
and stored at −80°C until use. In some cases, releasates were heated 
to 95°C for 30 minutes to denature proteins, then clarified by cen-
trifugation for 10 minutes at 13 000g. (Polyphosphate is stable during 
this heat treatment.29) In other cases, polyphosphate was degraded 
by incubating samples with recombinant yeast exopolyphosphatase 
(ScPPX1), as previously described.29 Effects of platelet releasates 
on cell differentiation were tested by incubating adherent cells for 
48 hours in medium with 1.5% serum plus 20-fold-diluted releasate 
(yielding a final releasate protein concentration of 15 µg/mL).
2.4 | Immunofluorescence
For immunofluorescence studies, cells were seeded on glass cov-
erslips at a density of 3.75 × 103 cells/cm2 in DMEM contain-
ing 2.5% serum and allowed to adhere overnight. The next day, 
cells were treated in fresh medium (with 2.5% serum) containing 
the desired stimulant for varying times, after which cells were 
washed once with Tris-buffered saline (TBS; 50 mmol/L Tris-Cl 
pH 7.5, 150 mmol/L NaCl) and fixed for 10 minutes at room tem-
perature using 4% paraformaldehyde in TBS. Cells were washed 
three times with TBS, permeabilized in TBS containing 0.2% 
Triton X-100 for 5 minutes, then washed again three times with 
TBS. Cells were then blocked in TBS plus 0.05% Tween-20 and 
5% bovine serum albumin for 1 hour at room temperature, after 
which they were incubated with primary antibody for 1 hour at 
room temperature in TBS plus 0.05% Tween-20 and 1% bovine 
serum albumin, and then washed three times with TBS. Cells 
were then incubated with secondary antibody plus SYBR green 
I (to stain DNA, 1:250 000 dilution) in TBS plus 0.05% Tween-
20 and 1% bovine serum albumin for 1 hour at room tempera-
ture in the dark. Cells were washed three times in TBS, briefly 
rinsed with water, and mounted onto glass microscope slides 
using Antifade Mountant. Samples were imaged the next day 
or stored at 4°C in the dark. Primary antibodies were used at 
the following dilutions: α-SMA at 1:1000, COL1A at 1:500, and 
vimentin at 1:100. Secondary antibodies were typically diluted 
1:500, whereas 647-conjugated phalloidin was diluted 1:1000. 
Images were obtained on a Leica SP5 confocal microscope (Leica 
Microsystems). A minimum of 25 individual cells from a minimum 
of five representative images were analyzed for each experiment. 
Integrated density (defined as product of cell area and mean fluo-
rescence intensity) was determined using ImageJ and the average 
integrated density for each experiment was determined.39 Cell 
body area was quantified using ImageJ.
2.5 | Migration assay
A total of 5 × 104 cells in DMEM were seeded in the top cham-
ber of a NUNC polycarbonate 24-well transwell (Thermo Fisher 
Scientific) migration assay in which the top chamber insert con-
tained an 8-micron porous membrane growth surface. Media with 
or without polyphosphate was added into the bottom chamber 
of the well to generate a polyphosphate gradient. Plates were 
incubated in a 5% CO2 environment at 37°C for 20 hours, after 
which cells in the bottom chamber were collected, subjected to 
one freeze/thaw cycle, and resuspended in RIPA lysis buffer. DNA 
was quantified in lysates using the CyQUANT proliferation assay 
using a SpectraMax i3x fluorescent microplate reader (Molecular 
Devices).
3  | RESULTS
3.1 | Ability of platelet releasates to induce 
myofibroblast differentiation in NIH 3T3 cells is 
largely dependent on its polyphosphate content
To characterize platelet-secreted factors that promote wound 
healing, we examined the ability of platelet releasates to induce 
differentiation of cultured fibroblastic cells into myofibroblasts, 
as depicted by increased α-SMA levels. Figure 1A reports a sig-
nificant increase in α-SMA levels in NIH-3T3 cells 48 hours after 
incubating the cells with platelet releasates in 1.5% serum, rel-
ative to cells cultured in the same medium without releasates. 
Releasates that had been heated to 95°C for 30 minutes exhib-
ited only a slightly diminished ability to induce an increase α-SMA 
levels in NIH-3T3 cells, suggesting that the activity was not due 
to a protein. The inorganic polymer, polyphosphate, is an emerg-
ing signaling molecule that is not a protein or peptide, and is re-
leased from dense granules of activated platelets.26 Furthermore, 
polyphosphate is relatively heat-stable under conditions that 
denature most proteins,17 so it seemed a good candidate for the 
differentiation-induce activity in platelet releasate. When plate-
let releasates were incubated with ScPPX1 to degrade polyphos-
phate,40 they lost most of their ability to increase α-SMA levels in 
NIH-3T3 cells. Finally, the combination of heat-treating the rele-
asates followed by digestion with ScPPX1 completely destroyed 
their ability to induce an increase in α-SMA levels in NIH-3T3 cells 
(P = 0.23). These data support the idea that the polyphosphate 
content of platelet releasates is essential for most of their ability 
to induce myofibroblast differentiation.
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3.2 | Platelet releasates also induce myofibroblast 
differentiation of primary human skin fibroblasts
NIH-3T3 cells are an established cell line derived from mouse embry-
onic fibroblasts. To examine whether polyphosphate could induce my-
ofibroblast differentiation in primary human cells, we cultured normal 
human dermal fibroblast cells (GM1381)41 under the same conditions 
we used for NIH-3T3 cells. As with NIH-3T3 cells, incubating GM1381 
cells with releasates from human platelets induced significant accu-
mulation of α-SMA, whereas this activity was substantially reduced 
when the releasates where digested with ScPPX1 (Figure 1B). As with 
NIH-3T3 cells, heat-treating the releasates resulted in only a modest 
decrease in accumulation of α-SMA by GM1381 cells. GM1381 cells 
incubated with platelet releasates that had been both heat-treated 
and digested with ScPPX1 showed no significant increase in α-SMA 
over control cells. Taken together, these findings show that primary 
human dermal fibroblasts respond to platelet-derived polyP in a man-
ner that is very similar to those of NIH-3T3 cells regarding induction 
of markers of myofibroblast differentiation.
3.3 | Platelet-sized polyphosphate induces 
hallmarks of myofibroblast differentiation
To assess directly if polyphosphate can act as a signaling mole-
cule for fibroblasts, we incubated NIH 3T3 cells with chemically 
synthesized polyphosphate (of approximately the size range re-
leased by activated platelets) in low-serum medium for 48 hours. 
As can be seen in Figure 2A, 5 µmol/L platelet-sized polyphos-
phate induced a robust increase in α-SMA levels which localized 
along stress fibers, both of which are hallmarks of differentiation 
into myofibroblasts.33,35 We further found that concentrations of 
platelet-size polyphosphate ranging from 0.1 to 25 µmol/L resulted 
in significantly increased α-SMA levels and stress fiber formation 
(Figure 2B and C). These polyphosphate concentrations are well 
within those expected in the presence of activated human plate-
lets.27 In addition to increased α-SMA levels and stress fiber for-
mation, fibroblasts increase in cell body size upon myofibroblast 
differentiation.42 Cells treated for 48 hours with 1 μmol/L platelet-
sized polyphosphate increased in cell body area (Figure 2D).
3.4 | Polyphosphate of a variety of polymer lengths 
induces myofibroblast differentiation
The biological effects of polyphosphate can depend strongly 
on polymer length.37 To evaluate the polymer length depend-
ence of polyphosphate's ability to induce myofibroblast dif-
ferentiation, we incubated NIH-3T3 cells for 48 hours with a 
series of narrowly sized fractioned polyphosphate preparations 
(all tested at 1 µmol/L) and evaluated α-SMA levels and stress 
fiber localization. Polyphosphate preparations ranging from 
F I G U R E  1   Platelet releasates induce myofibroblast differentiation, as evidenced by increased α-SMA levels. A, NIH-3T3 cells or (B) 
GM1381 cells were incubated in 1.5% serum in the presence or absence of releasates from activated human platelets (diluted to 15 µg/mL 
protein). As indicated, some releasates were previously heat-treated to denature proteins, or digested with ScPPX1 to destroy polyphosphate 
(red indicates treatment with ScPPX1). After 48 h, antibody staining for α-SMA was quantified by confocal microscopy as a marker of 
myofibroblast differentiation. All values are mean ± SEM (n = 5). Asterisks highlight statistical significance of the indicated comparisons: 
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14 to 1100 phosphates long showed significant ability to in-
duce α-SMA accumulation (Figure 2E), whereas polyphosphates 
ranging from 29 to 1100 phosphates in length supported in-
creased stress fiber formation (Figure 2F). These polymer 
lengths encompass those secreted by activated platelets, mast 
cells, and basophils, which are ~60 to 100 phosphates long, as 
well as those found in microbes, which can range up to more 
than 1000 phosphates long.
3.5 | Platelet-sized polyphosphate induces 
myofibroblast differentiation of primary human 
fibroblasts
We next examined whether polyphosphate could induce myofi-
broblast differentiation in primary human fibroblasts. GM1381 
cells were incubated for 48 hours with 1 or 5 µmol/L platelet-sized 
polyphosphate. Polyphosphate induced significant increases in the 
F I G U R E  2   Polyphosphate induces myofibroblast differentiation, as evidenced by increased α-SMA levels and stress fiber formation. A 
and C, Platelet-size polyphosphate (polyP) increases α-SMA levels in NIH-3T3 cells. A, Representative images in which NIH-3T3 cells were 
cultured in 1.5% serum in the absence (control) or presence of 5 µmol/L platelet-sized polyphosphate. After 48 h, cells were stained for 
α-SMA (red) or DNA (green) and imaged by confocal microscopy (bar = 10 µm). B and C, Dose-response of NIH-3T3 cells to platelet-size 
polyphosphate. In 5 experiments, cells were treated for 48 h in 1.5% serum plus the indicated concentrations of platelet-size polyphosphate, 
after which the following were quantified: (B) integrated intensity of α-SMA staining per cell, or (C) percent cells positive for α-SMA staining 
localized along fibrin tendrils (stress fibers). D, Platelet-size polyphosphate increases cell body area. NIH-3T3 cells were cultured in 1.5% 
serum in the absence or presence of 1 μmol/L polyphosphate for 48 h and imaged by confocal microscopy. Cell body area of individual cells 
was quantified. E and F, Polymer length-dependence of polyphosphate's ability to induce myofibroblast differentiation in NIH 3T3 cells. 
Cells were incubated in 1.5% serum for 48 h in the presence or absence of 1 µmol/L polyphosphate of the indicated polymer lengths (in 
phosphate units): (E) integrated intensity of α-SMA staining per cell, or (F) percent cells positive for α-SMA staining localized along fibrin 
tendrils (stress fibers). G, Dose-response of GM1381 cells to platelet-size polyphosphate. Cells were incubated in 1.5% serum with varying 
concentrations of platelet-size polyphosphate for 48 h, after which the integrated intensity of α-SMA staining was quantified. Values in 
panels B-C and E-G are mean ± SEM (n = 5). Asterisks highlight statistical significance relative to the no-polyphosphate controls: *P < 0.05, 
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levels of α-SMA, in a manner very similar to that observed with 
NIH-3T3 cells (Figure 2G).
3.6 | Polyphosphate increases polymerized 
actin levels
To determine if platelet-sized polyphosphate induced an increase in 
F-actin levels, we stained polyphosphate-treated NIH-3T3 cells with 
phalloidin. Polyphosphate increased F-actin levels within 24 hours, 
and by 48 hours showed clear fibril localization (Figure 3A and B). 
This further suggests that polyphosphate promotes the formation of 
actin stress fibers in fibroblastic cells.
3.7 | Polyphosphate increases collagen 
synthesis and vimentin levels
We next assessed if platelet-sized polyphosphate induced increases 
in other markers of myofibroblast differentiation. Myofibroblasts 
produce high levels of extracellular matrix proteins to propagate scar-
tissue formation and promote reepithelialization.35 Polyphosphate 
nanoparticles have previously been shown to increase collagen 
levels in the osteoblastic cell line MC3T3-E1, as well as in vivo 
when topically applied to skin lesions of mice.43 To determine if 
polyphosphate induces increased collagen synthesis in fibroblasts, 
NIH-3T3 cells were stained for collagen 1 alpha after incubation 
for 48 hours with platelet-sized polyphosphate. Polyphosphate 
F I G U R E  3   Polyphosphate increases other myofibroblast markers. A and B, phalloidin levels. NIH-3T3 cells were incubated in 1.5% 
serum for 24 or 48 h in the presence of the indicated concentrations of platelet-sized polyphosphate, after which phalloidin staining levels 
from confocal images were assessed. Images at 48 h are shown in panel B (representative of 5 experiments; bar = 10 µm). C and D, collagen 
type 1 alpha (COL-1A) levels. NIH-3T3 cells were incubated in 1.5% serum for 48 h in the presence or absence of 1 µmol/L platelet-sized 
polyphosphate, after which COL-1A staining levels from confocal images were assessed. D, representative images from 5 experiments. E and 
F, vimentin levels. NIH-3T3 cells were incubated in 1.5% serum for 48 h in the presence or absence of 1 µmol/L platelet-sized polyphosphate, 
after which vimentin staining levels from confocal images were assessed. F, representative images from 5 experiments. Values in panels A, C, 
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induced an increase in collagen production (Figure 3C and D). The 
intermediate filament vimentin is a mesenchymal marker that is 
important in wound healing, and increases upon myofibroblast dif-
ferentiation.44,45 Polyphosphate caused an increase in vimentin 
staining (Figure 3E and F). These data suggest that polyphosphate 
increases the synthesis of collagen and vimentin, both of which are 
markers of myofibroblasts.
3.8 | Polyphosphate is a chemoattractant for NIH-
3T3 cells
Tissue-resident fibroblasts are recruited to wound sites preced-
ing myofibroblast differentiation.33,35 Polyphosphate has been 
implicated in endothelial cell migration during bone and cartilage 
formation,46 modulates leukocyte migration,47 and acts as a che-
moattractant for human neutrophils.24 We therefore examined 
whether polyphosphate was a chemoattractant for NIH-3T3 cells 
by culturing NIH-3T3 cells in transwell migration plates with a gra-
dient of polyphosphate. Polyphosphate at 1 or 5 µmol/L enhanced 
NIH-3T3 migration toward the bottom chamber (Figure 4A). To 
test whether polyphosphate was a chemoattractant rather than 
simply enhancing motility, polyphosphate was incubated in the 
top, bottom, or both chambers of transwell migration plates. Cells 
incubated with polyphosphate in the top chamber remained in the 
upper chamber in higher numbers compared with untreated cells 
(Figure 4B). Polyphosphate incubated in both the top and bot-
tom chambers did not induce directional cell migration, whereas 
F I G U R E  4   Polyphosphate is a chemoattractant. A, NIH-3T3 cells were incubated in 1% serum for 20 h in the upper chamber of migration 
chambers, with the indicated concentrations of platelet-sized polyphosphate in the lower chamber. B, NIH-3T3 cells were incubated in 1% 
serum for 20 h with 5 μmol/L platelet-sized polyphosphate in the indicated chamber(s), or without polyphosphate (control). C, NIH-3T3 cells 
were incubated in 1% serum for 20 h in the upper chamber of migration chambers, with the indicated treatments of 3 μmol/L MRS2279 
or 5 μmol/L polyphosphate in the lower chamber. Control chambers received no treatment. After collecting and lysing the cells in the 
lower chamber, CyQUANT signals were expressed as relative fluorescence units (RFU) normalized to the no-polyphosphate control (set 
to 100 RFU). D, NIH-3T3 cells were cultured in 1.5% serum in the absence (control) or presence of 5 µmol/L platelet-sized polyphosphate 
or 3 μmol/L MRS2279. After 48 h, the integrated intensity of α-SMA staining was quantified. All values are mean ± SEM (n = 5). Asterisks 
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polyphosphate in just the bottom chamber resulted in directional 
cell migration (Figure 4B). The purinergic receptor P2Y1 mediates 
polyphosphate signaling in endothelial cells and astrocytes.32,48 
Blocking P2Y1 signaling with the high-affinity competitive an-
tagonist MRS 2279 effectively inhibited polyphosphate-induced 
migration (Figure 4C). Thus, in addition to inducing fibroblast 
differentiation, polyphosphate may also play a role in fibroblast 
recruitment, mediated by the P2Y1 receptor. In contrast, we 
found that MRS 2279 did not significantly diminish the ability of 
polyphosphate to induce α-SMA accumulation by NIH-3T3 cells 
(Figure 4D). This suggests that the differentiation-inducing ability 
of polyphosphate may act via different receptors than its chemo-
taxis-inducing ability.
4  | DISCUSSION
Here, we show that inorganic polyphosphate promotes myofibroblast 
differentiation in both the embryonic fibroblast-like cell line, NIH-3T3, 
and primary human dermal fibroblasts. Platelet-sized polyphosphate 
induced increased α-SMA expression, which localized along F-actin 
stress fibers, the two hallmarks of myofibroblast differentiation. 
Furthermore, polyphosphate promoted increased F-actin levels, colla-
gen synthesis, and vimentin levels. These data suggest that polyphos-
phate activates fibroblasts to differentiate into a tissue-remodeling 
phenotype that promotes contractile force generation to aid in wound 
closure, and increases tissue matrix protein synthesis to generate scar 
tissue, both essential to wound resolution.
Polyphosphates over a wide range of sizes promoted myofibro-
blast differentiation, with 29 phosphate groups being the minimum 
length necessary, and polymer lengths of up to 1100 phosphates 
showing activity. Eukaryotic cells such as Dictyostelium discoideum, 
mast cells, basophils, and platelets secrete relatively small chains of 
polyphosphate containing less than 100 phosphate groups.13,25,26 
Prokaryotic organisms, on the other hand, contain polyphosphates 
with more heterogeneous size distributions, often well over 1000 
phosphate units in length.37 It is therefore possible that microbial 
polyphosphate could also promote chemotaxis of fibroblasts and 
differentiation into myofibroblasts. Although severe bacterial in-
fection may be detrimental, low levels of bacterial colonization 
have actually been shown to be beneficial to wound healing.49
Polyphosphate is an emerging pro-migratory molecule, en-
hancing migration of the social amoeba Dictyostelium discoideum,15 
human endothelial cells,46 and human leukocytes.24,47 Our find-
ing that platelet-sized polyphosphate promoted chemotaxis of 
NIH-3T3 cells suggests that in addition to inducing differentia-
tion into a pro-wound healing and pro-fibrotic phenotype, poly-
phosphate may act to recruit fibroblasts to sites of tissue injury. 
The purinergic receptor P2Y1 mediates polyphosphate signaling 
in endothelial cells and astrocytes.32,48 Migration of NIH-3T3 
cells induced by polyphosphate was also mediated by P2Y1, add-
ing further evidence that P2Y1 may be a conserved receptor for 
polyphosphate in mammalian cells. In contrast, inhibiting P2Y1 
receptors did not appreciably diminish 3T3 cell differentiation into 
a myofibroblast phenotype, suggesting that this aspect of poly-
phosphate signaling uses different receptors.
Polyphosphate nanoparticles enhance wound healing in vivo, in-
creasing collagen and α-SMA levels in the osteoblast-like cell line, 
MC3T3.43 Here, we show that polyphosphate synthesized and re-
leased by human platelets recapitulated the effects of chemically 
synthesized polyphosphate on myofibroblast differentiation. This 
was demonstrated in experiments in which releasates from activated 
human platelets induced fibroblast differentiation, but this activity 
was largely eliminated following treatment of releasates with the poly-
phosphate-degrading enzyme, exopolyphosphatase, suggesting that 
polyphosphate is the major source of activity in platelet releasates. 
Polyphosphate released from activated platelets and other cell types 
at sites of tissue damage may therefore act as a pro-wound healing, cell 
signaling molecule for fibroblasts. It also suggests that polyphosphate 
may be an appealing therapeutic for treatment of chronic wounds.
In this study, platelet polyphosphate promoted myofibroblast 
differentiation of both murine fibroblastic cells and human pri-
mary dermal fibroblasts. Myofibroblasts drive fibrosis progres-
sion in tissues and organs, raising the intriguing possibility that 
polyphosphate, which also promotes the formation of the pro-fi-
brotic fibrocyte cell,24 may be a novel target for the suppression 
of fibrotic diseases, which account for 45% of all deaths in the 
United States.24,36 Patients with idiopathic pulmonary fibrosis 
show increased platelet reactivity and activation, which is due 
to a currently unknown plasma factor.50,51 Primary myelofibrosis, 
in which the normal spongy marrow of the bone is replaced by 
dense scar tissue, is thought to be driven in large part by mega-
karyocytes, which are responsible for platelet production.52,53 
Megakaryocytes contain pro-fibrotic molecules such as trans-
forming growth factor-beta and platelet-derived growth factor.53 
The role of platelet-derived and potentially megakaryocyte- 
derived polyphosphate in these fibrotic disorders has not been 
 investigated, but might provide insight into the progression of 
these fibrotic pathologies in the lung and bone marrow.
Mycobacterium tuberculosis and Trypanosoma cruzi are micro-
organisms that accumulate polyphosphate.54,55 In M tuberculosis, 
polyphosphate plays roles in infection persistence, survival, and vir-
ulence, while in T cruzi, polyphosphate is important for environmen-
tal stress adaptation.54,56-58 Tuberculosis infection can lead to the 
development of pulmonary fibrosis, whereas T cruzi infection can 
lead to the development of cardiac fibrosis.59-61 Microbial polyphos-
phate may therefore be a source of this fibrosis-inducing activity, 
which warrants further investigation.
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